ArticleCancer causes & control : CCC2026
Primary care continuity and breast cancer survival: a retrospective cohort study.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary care provider (PCP) continuity improves many health outcomes, but its impact on breast cancer survival remains unclear. We examined how baseline PCP continuity and use (in the 24 months before diagnosis) relate to overall survival in Ontario women with breast cancer.
methodsPopulation-based, retrospective cohort study, using linked provincial-level administrative health databases and cancer registries, including 13,171 women in Ontario diagnosed with stage I-III breast cancer between 2007 and 2012 who received curative surgery and adjuvant chemotherapy. We used Cox proportional hazards regression to examine the association between baseline PCP continuity and use with overall survival, determined up to 31 December 2020, adjusting for age, comorbidity, neighborhood income, and immigration status, and examined cancer stage as a potential mediator.
resultsNo PCP visits in the 24 months before diagnosis were associated with worse survival (HR for death 1.27, 95% CI 1.08-1.49). For those with PCP visits, low versus high continuity was not associated with survival in our adjusted analyses (HR 0.98, 95% CI 0.90-1.07). Treated linearly, each additional PCP visit in the 24 months before diagnosis, regardless of continuity, was associated with slightly worse survival (HR 1.01 per visit, 95% CI 1.00-1.01).
conclusionBaseline PCP continuity was not associated with overall survival in women with breast cancer in Ontario after adjusting for potential confounders. However, having no baseline PCP visits, or having a higher overall number of baseline PCP visits were associated with lower survival. Further research can clarify whether ensuring patients have access to any PCPs at baseline or providing added support for patients with many baseline PCP visits after a breast cancer diagnosis can improve survival outcomes.
Indexed as
Identifiers
42189262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.